Celon PharmaLTS:0RKX 48 Forward Dividend Yield % is 0.00% as of Jul. 06, 2026. GuruFocus rates LTS:0RKX with a GF Score™ of 48/100 and a GF Value™ of zł26.17. The stock has 3 warning signs investors should review. Among 507 Drug Manufacturers companies, Celon Pharma ranks worse than 197238.46% on this metric.
As of today (2026-07-06), the Forward Annual Dividend Yield of Celon Pharma is 0.00%.
As of today (2026-07-06), the Trailing Annual Dividend Yield of Celon Pharma is 0.00%.
LTS:0RKX's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.03 * Ranked among companies with meaningful Forward Dividend Yield % only.
During the past 12 months, Celon Pharma's average Dividends Per Share Growth Rate was -100.00% per year.
During the past 11 years, the highest 3-Year average Dividends Per Share Growth Rate of Celon Pharma was 4.60% per year. The lowest was -25.60% per year. And the median was -9.10% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Celon Pharma Forward Dividend Yield % Related Terms
LTS:0RKX vs ZTS, UTHR, VTRS: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celon Pharma Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Celon Pharma's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Celon Pharma (LTS:0RKX) has a Forward Dividend Yield % of 0.00% as of Jul. 06, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Celon Pharma and its competitors. According to the industry distribution chart, Celon Pharma ranks #999999 out of 507 companies in the Drug Manufacturers industry.
Is Celon Pharma's Forward Dividend Yield % too high?
Celon Pharma's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Celon Pharma ranks #999999 out of 507 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Celon Pharma has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's Forward Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Celon Pharma ranks #999999 out of 507 companies for Forward Dividend Yield %. This places Celon Pharma in the lower half of its industry. The industry median Forward Dividend Yield % is 2.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.03, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Celon Pharma and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celon Pharma's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Celon Pharma (LTS:0RKX) has a current Forward Dividend Yield % of 0.00%. The stock's GF Value™ is zł26.17, compared to a current price of zł22.50 — trading 14% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Celon Pharma's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Celon Pharma (LTS:0RKX), the current Forward Dividend Yield % is 0.00% as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Celon Pharma (LTS:0RKX) Overvalued in 2026?
Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued.
The current stock price of zł22.50 is trading 14% below its estimated GF Value™ of zł26.17.
Key valuation signals for LTS:0RKX:
Forward Dividend Yield %: 0.00%
GF Value™: zł26.17 vs. price of zł22.50 (14% below fair value)
No single metric tells the full story. See the LTS:0RKX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
48GF Score
Get the complete analysis for LTS:0RKX
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RKX has been successfully added to your 